Current Report Filing (8-k)
January 19 2022 - 04:11PM
Edgar (US Regulatory)
0001831363false00018313632022-01-192022-01-19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
|
|
Date of Report (Date of earliest event reported):
January 19, 2022
|
Terns Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
Delaware
|
001-39926
|
98-1448275
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
|
|
1065 East Hillsdale Blvd.
Suite 100
|
|
|
Foster City,
California
|
|
94404
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
|
Registrant’s Telephone Number, Including Area Code:
(650)
525-5535
|
(Former Name or Former Address, if Changed Since Last
Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, $0.0001 par value per share
|
|
TERN
|
|
NASDAQ Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 8.01 Other Events.
On January 19, 2022, Terns Pharmaceuticals, Inc. (the “Company”)
announced that Senthil Sundaram, the Company’s chief executive
officer, has been diagnosed with cancer and will undergo aggressive
treatment, including chemotherapy. Mr. Sundaram plans to continue
in his role as chief executive officer during his treatment period
and to work closely with the Company’s board of directors and
management team to execute on the Company’s business priorities. It
is expected that Mr. Sundaram will limit certain business
activities, including travel, during his treatment.
The Company requests that Mr. Sundaram’s privacy be respected
during this period.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
|
|
TERNS PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
Date:
|
January 19, 2022
|
By:
|
/s/ Bryan Yoon
|
|
|
|
|
Bryan Yoon
Chief Operating Officer & General Counsel
|
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Apr 2022 to May 2022
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From May 2021 to May 2022
